On Tuesday, Aquestive Therapeutics Inc (NASDAQ: AQST) was 0.18% up from the session before settling in for the closing price of $2.83. A 52-week range for AQST has been $2.20 – $5.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2.34% over the past five years. When this article was written, the company’s average yearly earnings per share was at -30.07%. With a float of $87.78 million, this company’s outstanding shares have now reached $91.41 million.
Let’s look at the performance matrix of the company that is accounted for 142 employees. In terms of profitability, gross margin is 68.95%, operating margin of -53.46%, and the pretax margin is -76.7%.
Aquestive Therapeutics Inc (AQST) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aquestive Therapeutics Inc stocks. The insider ownership of Aquestive Therapeutics Inc is 11.22%, while institutional ownership is 38.87%. The most recent insider transaction that took place on Nov 26 ’24, was worth 214. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $4.87, taking the stock ownership to the 0 shares.
Aquestive Therapeutics Inc (AQST) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 13.68% during the next five years compared to 27.90% growth over the previous five years of trading.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
You can see what Aquestive Therapeutics Inc (AQST) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.36. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.52, a number that is poised to hit -0.17 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Aquestive Therapeutics Inc (NASDAQ: AQST) saw its 5-day average volume 0.83 million, a negative change from its year-to-date volume of 1.55 million. As of the previous 9 days, the stock’s Stochastic %D was 76.10%. Additionally, its Average True Range was 0.19.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 24.42%, which indicates a significant decrease from 82.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 54.42% in the past 14 days, which was lower than the 68.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.81, while its 200-day Moving Average is $3.80. Nevertheless, the first resistance level for the watch stands at $2.92 in the near term. At $3.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.10. If the price goes on to break the first support level at $2.74, it is likely to go to the next support level at $2.64. Assuming the price breaks the second support level, the third support level stands at $2.56.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
There are 98,871K outstanding shares of the company, which has a market capitalization of 281.57 million. As of now, sales total 57,560 K while income totals -44,140 K. Its latest quarter income was 11,870 K while its last quarter net income were -17,060 K.
